# A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

> **NCT02349451** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 240 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **BIOLOGICAL:** adalimumab
- **BIOLOGICAL:** ABT-122

## Key facts

- **NCT ID:** NCT02349451
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-28
- **Primary completion:** 2016-07-04
- **Final completion:** 2016-07-04
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2017-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349451, "A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02349451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*